Status:
WITHDRAWN
Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease
Lead Sponsor:
Pontificia Universidad Catolica de Chile
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Kawasaki Disease
Eligibility:
All Genders
8-25 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether Chilean children with history of Kawasaki disease have endothelial dysfunction years after the acute phase of the disease, and if this condition can b...
Detailed Description
Kawasaki disease (KD) in its acute phase produces endothelial inflammation that can lead to dilatation and aneurysms of coronary and peripheral arteries. This initial injury leads to persistent endoth...
Eligibility Criteria
Inclusion
- History of Kawasaki disease more than 12 months before enrollment
- Present age of 8 years or older
Exclusion
- Diabetes mellitus
- Not controlled hypertension
- Treatment with drugs thay modify endothelial function such as angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium channel blockers
- Smokers of more than 5 cigarettes per day
- Total cholesterol higher than 250 mg/dl
- Triglycerides higher than 300mg/dl
- Chronic treatment with statins
- Chronic renal insufficiency (creatinine \> 1.5 mg/dl)
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00305201
Start Date
April 1 2006
End Date
May 1 2007
Last Update
May 24 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pontificia Universidad Catolica de Chile, School of Medicine
Santiago, Santiago Metropolitan, Chile